Please login to the form below

Not currently logged in

AZ’s Tagrisso cuts risk of EGFR-positive NSCLC spreading to the brain

Results showing EGFR-inhibitor improves outcomes in adjuvant setting released at ESMO 2020 virtual congress

AstraZeneca’s Tagrisso cuts the risk of EGFR-positive lung cancer patients developing brain metastases, according to new data revealed by the company on Saturday.

Tagrisso (osimertinib), a third-generation EGFR inhibitor, demonstrated a clinically meaningful improvement in central nervous system (CNS) disease-free survival (DFS) in the treatment of patients with early-stage EGFR-positive non-small cell lung cancer (NSCLC) after complete tumour resection.

The results, from the phase 3 ADAURA trial, were presented at the 2020 European Society for Medical Oncology (ESMO) virtual congress and also simultaneously published in The New England Journal of Medicine.

These detailed results showed that fewer patients treated with Tagrisso in the adjuvant setting had recurrence event or death compared to placebo – 11% and 46% respectively.

For those patients whose cancer did recur, 38% had a metastatic recurrence, compared to 61% of patients on the placebo arm. In addition, Tagrisso treatment also reduced the risk of CNS recurrence or death by 82%, although median CNS DFS was not reached yet in either arm of the study.

“The striking new data shows that Tagrisso prevents the development of brain metastases in patients with early disease and reinforces that this medicine is truly transformative for patients with EGFR-mutated lung cancer,” said José Baselga, executive vice president of Oncology R&D at AZ.

According to AZ, CNS recurrence – in which the cancer spreads to the brain – is frequently observed in patients with EGFR-positive NSCLC and carries with it an ‘especially poor prognosis’. Approximately a quarter of global lung cancer cases are EGFR-mutated, although in Asia the rate can climb to over 40% of new cases.

In previous studies of Tagrisso, the EGFR inhibitor was able to extend survival in previously untreated patients with EGFR-positive NSCLC cancer, showing an improvement over other drugs in the class, including AZ’s own Iressa (gefitinib) and Roche’s Tarceva (erlotinib).

In the first half of the year, revenues for Tagrisso jumped by 43% to $2bn, thanks to its approval and dominance in advanced or metastatic EGFR-mutated NSCLC.

“Tagrisso should become the standard of care in the adjuvant setting, just as it is for patients with metastatic disease around the world,” added Baselga.

Article by
Lucy Parsons

21st September 2020

From: Research



COVID-19 Updates and Daily News

Featured jobs


Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

1000 Voices Survey
The patient voice is key to creating meaningful changes in healthcare; to drive patients to be more actively involved in their care, which leads to better outcomes. So, we went...
COVID-19 vaccine
How will COVID-19 affect uptake of vaccinations against other diseases?
Will COVID-19 help or hinder the quest to increase uptake of other vaccinations?...
How community outreach can help improve diversity in clinical research
To execute a considered community engagement strategy, an involved and collaborative process is needed....